Delayed clearance of viral load and marked cytokine activation in severe cases of pandemic H1N1 2009 influenza virus infection

Kelvin K W To, Ivan F N Hung, Iris W S Li, Kar-Lung Lee, Chi-Kwan Koo, Wing-Wa Yan, Raymond Liu, Ka-Ying Ho, Kwok-Hong Chu, Chi-Leung Watt, Wei-Kwang Luk, Kang-Yiu Lai, Fu-Loi Chow, Thomas Mok, Tom Buckley, Jasper F W Chan, Samson S Y Wong, Bojian Zheng, Honglin Chen, Candy C Y Lau, Herman Tse, Vincent C C Cheng, Kwok-Hung Chan, Kwok-Yung Yuen, Kelvin K W To, Ivan F N Hung, Iris W S Li, Kar-Lung Lee, Chi-Kwan Koo, Wing-Wa Yan, Raymond Liu, Ka-Ying Ho, Kwok-Hong Chu, Chi-Leung Watt, Wei-Kwang Luk, Kang-Yiu Lai, Fu-Loi Chow, Thomas Mok, Tom Buckley, Jasper F W Chan, Samson S Y Wong, Bojian Zheng, Honglin Chen, Candy C Y Lau, Herman Tse, Vincent C C Cheng, Kwok-Hung Chan, Kwok-Yung Yuen

Abstract

Background: Infections caused by the pandemic H1N1 2009 influenza virus range from mild upper respiratory tract syndromes to fatal diseases. However, studies comparing virological and immunological profile of different clinical severity are lacking.

Methods: We conducted a retrospective cohort study of 74 patients with pandemic H1N1 infection, including 23 patients who either developed acute respiratory distress syndrome (ARDS) or died (ARDS-death group), 14 patients with desaturation requiring oxygen supplementation and who survived without ARDS (survived-without-ARDS group), and 37 patients with mild disease without desaturation (mild-disease group). We compared their pattern of clinical disease, viral load, and immunological profile.

Results: Patients with severe disease were older, more likely to be obese or having underlying diseases, and had lower respiratory tract symptoms, especially dyspnea at presentation. The ARDS-death group had a slower decline in nasopharyngeal viral loads, had higher plasma levels of proinflammatory cytokines and chemokines, and were more likely to have bacterial coinfections (30.4%), myocarditis (21.7%), or viremia (13.0%) than patients in the survived-without-ARDS or the mild-disease groups. Reactive hemophagocytosis, thrombotic phenomena, lymphoid atrophy, diffuse alveolar damage, and multiorgan dysfunction similar to fatal avian influenza A H5N1 infection were found at postmortem examinations.

Conclusions: The slower control of viral load and immunodysregulation in severe cases mandate the search for more effective antiviral and immunomodulatory regimens to stop the excessive cytokine activation resulting in ARDS and death.

Figures

Table 1
Table 1
Demographic Characteristics and Underlying Comorbidities
Table 2
Table 2
Investigations, Treatments, Complications, and Clinical Outcomes
Table 3
Table 3
Initial Plasma Cytokine or Chemokine Levels and Viral Load in Respiratory Specimens
Figure 1
Figure 1
Nasopharyngeal viral load in patients with different clinical severity, according to number of days after symptom onset (A) and to number of days after initiation of oseltamivir treatment (B). Horizontal dotted line indicates detection limit of reverse-transcription polymerase chain reaction. ARDS, acute respiratory distress syndrome.
Figure 2
Figure 2
Plasma cytokine or chemokine level, stratified by days after symptom onset. Median, quartiles, and range are shown. The Jonckheere-Terpstra trend test was used to compare cytokine level with disease severity. Horizontal dotted line detection limit of the assay. A Granulocyte colony-stimulating factor. B Interferon (IFN)– lpha;2. C Interleukin (IL)–1 lpha;. D IL-6. E IL-8. F IL-10. G IL-15. H IL-17. I IFN- amma;–induced protein 10. J Monocyte chemoattractant protein–1. K Tumor necrosis factor-α.
Figure 3
Figure 3
Histopathological changes of pulmonary and extrapulmonary tissue (hematoxylin-eosin stained) of the deceased patients suffering from pandemic influenza A H1N1 2009. A Lung parenchyma showing acute exudative phase of diffuse alveolar damage on day 7 after symptom onset in a 42-year-old previously healthy man with interstitial cellular infiltrate and proteinaceous exudates in alveoli and hyaline membrane formation (original magnification, imes;100). B Lung parenchyma showing chronic fibroproliferative phase of diffuse alveolar damage with marked thickening of the alveolar septa and alveolar space being replaced by fibrogranulation tissues on day 28 of symptom onset in a 37-year-old previously healthy woman (original magnification, imes;200). C Thrombosis of branches of pulmonary artery in the same patient in panel B who died despite extracorporeal membrane oxygenation (original magnification, imes;200). D Lymphoid atrophy with no recognizable germinal centre in the spleen of the same patient in panels B and C. The periarteriolar lymphoid sheath (white pulp), which was markedly reduced in size (original magnification, imes;400). E Myocardium showing a microscopic focus of lymphoid aggregate accompanied by myofibril necrosis in a 58-year-old man presenting with elevated creatine kinase isoenzyme CK-MB and echocardiographic evidence of diastolic dysfunction (original magnification, imes;200). F Mediastinal lymph node showing reactive hemophagocytosis in the same patient in panel E (original magnification, imes;400).

References

    1. Wong SS, Yuen KY. Avian influenza virus infections in humans. Chest. 2006;129:156–168.
    1. Chowell G, Bertozzi SM, Colchero MA, et al. Severe respiratory disease concurrent with the circulation of H1N1 influenza. N Engl J Med. 2009;361:674–679.
    1. Trifonov V, Khiabanian H, Rabadan R. Geographic dependence, surveillance, and origins of the 2009 influenza A (H1N1) virus. N Engl J Med. 2009;361:115–119.
    1. Munster VJ, de Wit E, van den Brand JM, et al. Pathogenesis and transmission of swine-origin 2009 A(H1N1) influenza virus in ferrets. Science. 2009;325:481–483.
    1. Maines TR, Jayaraman A, Belser JA, et al. Transmission and pathogenesis of swine-origin 2009 A(H1N1) influenza viruses in ferrets and mice. Science. 2009;325:484–487.
    1. Itoh Y, Shinya K, Kiso M, et al. In vitro and in vivo characterization of new swine-origin H1N1 influenza viruses. Nature. 2009;460:1021–1025.
    1. Hanshaoworakul W, Simmerman JM, Narueponjirakul U, et al. Severe human influenza infections in Thailand: oseltamivir treatment and risk factors for fatal outcome. PLoS One. 2009;4:e6051.
    1. Jamieson DJ, Honein MA, Rasmussen SA, et al. H1N1 2009 influenza virus infection during pregnancy in the USA. Lancet. 2009;374:451–458.
    1. Centers for Disease Control and Prevention (CDC) Intensive-care patients with severe novel influenza A (H1N1) virus infection- Michigan, June 2009. MMWR Morb Mortal Wkly Rep. 2009;58:749–752.
    1. Yuen KY, Chan PK, Peiris M, et al. Clinical features and rapid viral diagnosis of human disease associated with avian influenza A H5N1 virus. Lancet. 1998;351:467–471.
    1. Woo PC, Tung ET, Chan KH, Lau CC, Lau KP, Yuen KY. Cytokine profiles induced by the novel swine-origin influenza A/H1N1 virus: implications on treatment strategies. J Infect Dis. 2010;201:346–353.
    1. Cheng VC, Tai WM, Wong LM, et al. J Hosp Infect. 2010. Prevention of nosocomial transmission of swine-origin pandemic influenza virus A/H1N1 by infection control bundle. [Epub ahead of print]
    1. Knaus WA, Draper EA, Wagner DP, Zimmerman JE. APACHE II: a severity of disease classification system. Crit Care Med. 1985;13:818–829.
    1. Bernard GR, Artigas A, Brigham KL, et al. The American-European Consensus Conference on ARDS. Definitions, mechanisms, relevant outcomes, and clinical trial coordination. Am J Respir Crit Care Med. 1994;149:818–824.
    1. Estenssoro E, Reina R, Canales HS, et al. The distinct clinical profile of chronically critically ill patients: a cohort study. Crit Care. 2006;10:89.
    1. Lau SK, Chan KH, Yip CC, et al. Confirmation of the first Hong Kong case of human infection by novel swine origin influenza A (H1N1) virus diagnosed using ultrarapid, real-time reverse transcriptase PCR. J Clin Microbiol. 2009;47:2344–2346.
    1. To KK, Chan KH, Li IW, et al. Viral load in patients infected with pandemic H1N1 2009 influenza virus. J Med Virol. 2010;82:1–7.
    1. Chen H, Cheung CL, Tai H, et al. Oseltamivir-resistant influenza A pandemic (H1N1) 2009 virus, Hong Kong, China. Emerg Infect Dis. 2009;15:1970–1972.
    1. Ieven M, Ursi D, Van Bever H, Quint W, Niesters HG, Goossens H. Detection of Mycoplasma pneumoniae by two polymerase chain reactions and role of M. pneumoniae in acute respiratory tract infections in pediatric patients. J Infect Dis. 1996;173:1445–1452.
    1. Gaydos CA, Quinn TC, Eiden JJ. Identification of Chlamydia pneumoniae by DNA amplification of the 16S rRNA gene. J Clin Microbiol. 1992;30:796–800.
    1. Li IW, Chan KH, To KW, et al. Differential susceptibility of different cell lines to swine-origin influenza A H1N1, seasonal human influenza A H1N1, and avian influenza A H5N1 viruses. J Clin Virol. 2009;46:325–330.
    1. Moltedo B, Lopez CB, Pazos M, Becker MI, Hermesh T, Moran TM. Cutting edge: stealth influenza virus replication precedes the initiation of adaptive immunity. J Immunol. 2009;183:3569–3573.
    1. de Jong MD, Tran TT, Truong HK, et al. Oseltamivir resistance during treatment of influenza A (H5N1) infection. N Engl J Med. 2005;353:2667–2672.
    1. Kidd IM, Down J, Nastouli E, et al. H1N1 pneumonitis treated with intravenous zanamivir. Lancet. 2009;374:1036.
    1. Svitek N, Rudd PA, Obojes K, Pillet S, von Messling V. Severe seasonal influenza in ferrets correlates with reduced interferon and increased IL-6 induction. Virology. 2008;376:53–59.
    1. de Jong MD, Simmons CP, Thanh TT, et al. Fatal outcome of human influenza A (H5N1) is associated with high viral load and hypercytokinemia. Nat Med. 2006;12:1203–1207.
    1. McKinstry KK, Strutt TM, Buck A, et al. IL-10 deficiency unleashes an influenza-specific Th17 response and enhances survival against high-dose challenge. J Immunol. 2009;182:7353–7363.
    1. Corsini E, Vismara L, Lucchi L, et al. High interleukin-10 production is associated with low antibody response to influenza vaccination in the elderly. J Leukoc Biol. 2006;80(2):376–382.
    1. Fehniger TA, Caligiuri MA. Interleukin 15: biology and relevance to human disease. Blood. 2001;97:14–32.
    1. Yin J, Dai A, Laddy DJ, et al. High dose of plasmid IL-15 inhibits immune responses in an influenza non-human primates immunogenicity model. Virology. 2009;393:49–55.
    1. Iwakura Y, Nakae S, Saijo S, Ishigame H. The roles of IL-17A in inflammatory immune responses and host defense against pathogens. Immunol Rev. 2008;226:57–79.
    1. Zheng BJ, Chan KW, Lin YP, et al. Delayed antiviral plus immunomodulator treatment still reduces mortality in mice infected by high inoculum of influenza A/H5N1 virus. Proc Natl Acad Sci U S A. 2008;105:8091–8096.
    1. Hung if, Cheng VC, Wu AK, et al. Viral loads in clinical specimens and SARS manifestations. Emerg Infect Dis. 2004;10:1550–1557.
    1. Gu J, Xie Z, Gao Z, et al. H5N1 infection of the respiratory tract and beyond: a molecular pathology study. Lancet. 2007;370:1137–1145.
    1. Centers for Disease Control and Prevention (CDC) Bacterial coinfections in lung tissue specimens from fatal cases of 2009 pandemic influenza A (H1N1)- United States, May-August 2009. MMWR Morb Mortal Wkly Rep. 2009;58:1071–1074.
    1. Taubenberger JK, Morens DM. The pathology of influenza virus infections. Annu Rev Pathol. 2008;3:499–522.

Source: PubMed

3
订阅